TSTickerStarGet alerts

Medicus Pharma regains conditional Nasdaq equity compliance

Nasdaq notified Medicus Pharma on November 18, 2026 that it regained compliance with Listing Rule 5550(b)(1), which requires at least $2.5 million in shareholders' equity for continued listing on the Nasdaq Capital Market. Nasdaq based its determination on approximately $4.25 million of completed equity financings and a $10.5 million debt exchange for non-convertible preferred shares. Compliance remains conditional on Medicus evidencing continued compliance in its next periodic report for the period ending Decem...

Share this story

Key takeaways

  • Nasdaq confirmed that Medicus regained compliance with Listing Rule 5550(b)(1) in a notice received on November 18, 2026.

  • The continued-listing rule requires at least $2.5 million in shareholders' equity.

  • Medicus completed approximately $4.25 million of equity financings, consisting of a $3.0 million registered direct offering and approximately $1.25 million of private placements led by company insiders.

  • Dr. Raza Bokhari invested $750,000 through a controlled entity as part of the insider-led private placements.

  • The company exchanged $10.5 million of indebtedness held by Streeterville Capital, LLC for non-convertible preferred shares.

  • Continued compliance must be demonstrated in the next periodic report for the period ending December 31, 2026, or the company may be subject to delisting.

  • The company remains subject to Nasdaq's other continued-listing requirements.

Key metrics

Nasdaq minimum shareholders' equity requirement
$2.5 million
Total equity financings
approximately $4.25 million
Registered direct offering
$3.0 million
Insider-led private placements
approximately $1.25 million
Investment by Dr. Raza Bokhari through a controlled entity
$750,000
Indebtedness exchanged for non-convertible preferred shares
$10.5 million

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow MDCX in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert